Nine Staphylococcus aureus strains isolated from patients with toxic shock syndrome (TSS), two strains from non-disease-associated sources, and four strains from disease (not TSS)-associated sources were characterized for the intraperitoneal dose necessary to kill 50% of exposed animals (LD50) and toxic shock toxin production and studied for synergistic effects on mouse mortality and morbidity when combined with a sublethal dose of Candida albicans and inoculated intraperitoneally. Representative toxic shock toxin-producing strains (free of other enterotoxins) exhibited the following unique set of characteristics when inoculated intraperitoneally into mice and compared with all other strains tested: (i) lowest virulence when inoculated alone into mice as determined by the LD50; (ii) greatest synergistic decrease in LD50 (up to 70,000-fold as compared to up to 200-fold for other strains) when combined with C. albicans and injected intraperitoneally; and (iii) induced a characteristic, dose-independent, temporal death pattern in dually injected animals. When sublethal dual doses were used, animals receiving disease (TSS and not TSS)-associated S. aureus in combination with C. albicans developed symptoms, but some differences in symptomatologies, depending on the strain, were observed. The symptoms included conjunctivitis; gastrointestinal, neurological, and circulatory abnormalities; rash followed by desquamation; and patchy baldness. Although overlap in symptoms between animal treatment groups was observed, certain symptoms (neurological sequeae and petechial hemorrhages) were observed only in animals inoculated with a specific S. aureus strain combined with C. albicans. Animals receiving sublethal dual doses, which included non-disease-associated S. aureus, did not develop symptoms. When Staphylococcus epidermidis was combined with C. albicans and inoculated into mice, no synergistic effects on morbidity or mortality were observed.
It was reported previously that dual intraperitoneal (i.p.) inoculation of Staphylococcus aureus 2460 (isolated from a toxic shock syndrome [TSS] patient) and Candida albicans resulted in a strong synergistic effect on mouse mortality (4) . As noted in that paper, the study was initially prompted by the observation that many epidemiological features of TSS mirror those of inveterate mycotic vulvovaginitis. For example, in both diseases outbreaks occur repeatedly and either immediately before the menstrual period (vulvovaginitis) (10, 14, 26) or during it (TSS) (8) . In addition, although no study has been done, clinical literature notes that S. aureus and Streptococcus spp. are frequently found to accompany candidosis (16, 18) , and in vitro C. albicans has been reported to enhance the growth of S. aureus (27) .
The initial study demonstrated a synergistic relationship between one TSS-associated S. aureus strain and C. albicans on mortality in dually inoculated mice (4) . This study was designed to examine: (i) whether the effect on mortality was general or differed depending on the source or ability of S. aureus strains to produce toxic shock toxin (TS toxin), and (ii) symptoms in animals given sublethal dual doses of C. albicans and various strains of S. aureus. Since TS toxin has been found to be associated with TSS strains (3, 23) , all strains in this study were characterized for ability to produce this toxin.
(This toxin was previously called pyrogenic exotoxin C [23] LDs.5 The i.p. LD50 was determined by the moving average method (2) for each strain of S. aureus by the standard procedure described previously (4) . Groups of six or more animals were given doses of each S. aureus strain to determine at least one dose which resulted in no mortality, one dose giving complete mortality, and two doses yielding partial mortality. Where no dose tested yielded a non-mortality group, probit analysis was employed to determine the LD50 (12) .
TS toxin. The presence of TS toxin and enterotoxins was determined under the direction of J. J. Kirkland (manuscript describing method submitted for publication) at the Procter and Gamble Co., Miami Laboratories, Cincinnati, Ohio, and M. S. Bergdoll, University of Wisconsin, Madison, by methods previously described (20) . RESULTS
Strains of S. aureus used, phage senitivities, production of TS toxin, enterotoxins A to E, and i.p. LD50 for mice are given in Table 1 . Seven of the nine TSS-associated strains produced TS toxin, whereas only one of the five non-TSSassociated tested did. Four of the strains producing TS toxin and no other enterotoxin were among the most nonvirulent as judged by the i.p. LD50 in mice, which was greater than 1010 CFU. This LD50 is comparable to that of the S. aureus strains from nondisease sources and the S. epidermidis strain tested.
The effect on mouse mortality of combined doses of C. albicans and S. aureus is shown in Table 2 . Doses could be determined for both TSS-associated and non-TSS-associated strains of S. aureus which caused little or no mortality alone and 100% or near 100% mortality in combination with nonlethal doses of C. albicans, whereas the S. epidermidis strain did not exhibit this effect. Sacrifice of animals injected with C.
albicans ( epidermidis alone. Figure 1 gives a temporal mortality analysis of six representative dualdose experiments employing two TSS-, two nondisease-, and two disease (not TSS)-associated S. aureus strains. It can be seen that the fungalbacterial combinations employing TSS-associated bacterial strains resulted in nearly synchronous animal deaths between 35 and 45 h after inoculation; non-disease-associated strains caused sporadic deaths over a 3-day period, and disease (not TSS)-associated strains resulted in 100% mortality in less than 12 h. In the experiments shown in Fig. 1 , only the TSS-associated strains produced TS toxin. The temporal death pattern in animals infected with C. albicans and the TSS-associated strains which did not produce TS toxin (TSS56 and TSS69) resembled that of the other strains isolated from human (not TSS) disease, with an average time between the fungal-bacterial injection and death of 11 and 14 h, respectively ( Table 2 ). The one TS toxinproducing strain not associated with TSS, FRI-1220, caused, with C. albicans, animal death in an average of 39 h (Table 2) , which was similar to the time of deaths caused by other TS toxinproducing strains in combination with C. albicans. (TS toxin-producing strains, when injected in lethal amounts alone into mice, produced sporadic deaths throughout the 3-day period after injection, whereas all 7 of 10 animals dying from twice the LD50 of C. albicans alone died within 12 h on days 2 and 3 after injection.) The results given were obtained with male animals, but no differences were found when experiments were repeated with females.
In another set of experiments, the effect of the size of the S. aureus dose in combination with C. albicans on mortality was examined. This was done by determining the LD50 in male mice of representative S. aureus strains in combination with 108 CFU of C. albicans. It can be seen in Table 3 that the LD50 of TS toxin-producing strains could be reduced by three to four orders of magnitude before its ability to kill half of the exposed mice when combined with C. albicans was lost, whereas the LD50 of non-TS toxinproducing strains was reduced by only one to two orders of magnitude before this effect was lost. The average elapsed time between injection and death was relatively unrelated to size of dose in the case of TS toxin-producing S. aureus strains, which could be reduced two orders of magnitude with no change in average number of hours between inoculation and death (data not shown). In the case of other strains, an indirect relationship between dose and time of death was observed. No mortality was observed in a group of six animals receiving 108 CFU of C. albicans alone.
To study morbidity in dually injected animals, females were dually injected with small doses of the two pathogens shown previously to cause partial mortality in the 5 days after injection. In all cases, 5.0 x 107 CFU of C. albicans was f Symptom was observed during the first 2 days. g Symptom of diarrhea was observed during first 2 days; this was frequently followed by the appearance of constipation. Due to difficulty in scoring individual animals, + was used to indicate the presence of this symptom in the treatment group.
h Symptom was observed on feet, ears, and tail between 9 and 11 days, resulting in death within 48 h after appearance. Further evidence of vascular failure was indicated by accumulation of uncontaminated fluid in the abdomen.
Bacterial dose in this case was 5 x 104 CFU.
-, Symptom not observed.
combined with 106 CFU of each of the representative strains of S. aureus (except strain FRI-1169, for which a dose of 5.0 x 104 CFU was used) and inoculated i.p. These animals were closely observed for morbidity and mortality for 6 weeks. The findings are summarized in Table  4 . Although some symptoms varied according to S. aureus strain, all animals for which the S. aureus strain was disease associated (TSS or not TSS) showed body redness in the shaved area of the back, gastrointestinal abnormalities (diarrhea followed by constipation) within 24 h of injections, patchy baldness (hair did not grow back normally, with animals still bald or showing patchy tufts of hair 1 month after last clipping), and some degree of mortality during the course of the observations. Animal groups receiving C. albicans and non-disease-associated S. aureus ATCC 25923 or S. epidermidis exhibited no symptoms. Certain C. albicans-S. aureus strain combinations caused flaking desquamation of the shaved back skin between 9 and 15 days, neurological sequelae (3 to 5 weeks after inoculation, animals exhibited a constantly tilted head and body), and petechial hemorrhages (small hemorrhages easily visible on feet, ears, tail, and shaved backed area appearing 6 to 10 days after injection). Animals developing petechial hemorrhages died within 3 days after this symptom was observed. Control animals receiving 106 CFU i.p. of S. aureus alone showed no symptoms. Nearly 50% of the animals receiving 5 .0 x 107 CFU of C. albicans i.p. showed body redness and gastrointestinal abnormalities, although to a lesser extent than animals receiving dual pathogen injections. No other symptoms were observed in control animals receiving either pathogen alone at these doses.
Two months after injections, seven representative animals were sacrificed from dually injected groups, and organs and tissues were examined to determine titers of S. aureus, C. albicans, and other bacteria. Infections due to the injected pathogens were found in abscesses associated with the liver and pancreas in all animals examined. Abscesses from two of the seven also contained additional organisms. Bacteria found along with S. aureus and C. albicans were Streptococcus group D, Streptococcus he-VOL. 42, 1983 on October 28, 2017 by guest http://iai.asm.org/ To examine the possibility of sex differences, the effects of a sublethal dose of C. albicans (108 CFU) and S. aureus C-3 (106 CFU) on a group of 10 female mice was compared with a group of 10 male mice with identical treatment. Both male and female animal groups showed similar mortality, petechial hemorrhages, and other symptoms, except that whereas 50% of the females showed patchy baldness, no males exhibited this symptom. This sex-associated difference was reproducible in five subsequent trials with different S. aureus strains.
Experiments were also conducted to determine how long after C. albicans infection various S. aureus strains could be added before the synergistic effect on mouse mortality was destroyed. Table 5 shows that for all S. aureus strains, the effect decreased with time and was lost completely when S. aureus injection followed C. albicans by 48 h. DISCUSSION Schlievert et al. (23) and Bergdoll et al. (3) have found a high degree of association between the presence of TS toxin and TSS involvement of S. aureus strains. However, the role of this toxin in the disease process remains obscure. In rabbits, using injection of the bacteria into subcutaneous chambers to assess the virulence, TSS strains proved more virulent than non-TSS strains (24) . Meanwhile, Barbour (1), using culture filtrates, found TSS strains less toxic than non-TSS strains to both chicken embryos and rabbits when injected intravenously.
In the experimental mouse system reported here, TS toxin-producing TSS strains (producing no other enterotoxins), inoculated i.p., were found to be among the least virulent of the strains tested. TS toxin-producing TSS strains of a greater virulence, equivalent to disease (not TSS) strains, all produced additional enterotoxins or, in the case of S. aureus TSS55 and TSS67, probably elaborated more hemolysins, as indicated by appearance on sheep blood agar. Therefore, it is concluded that strains which produce TS toxin in the absence of other toxins are of low virulence to mice due either to lack of toxin production in the experimental system or to the need for some additional underlying condition or activating factor. Since in the presence of C. albicans these strains are among the most lethal, it seems reasonable to conclude that TS toxin is probably toxic to mice, at least under certain conditions, although a role of hemolysins in morbidity and mortality cannot be ruled out.
Kapral (15) reported that TSS-associated strains of S. aureus have a hemolysin pattern similar to that of other strains, whereas Chow et al. (7) found that the vaginal TSS isolates were more likely to produce 8-hemolysin alone and also differed as a group by producing smaller amounts of all hemolysins. The exceptionally high LD50s of TS toxin-producing strains suggest a lack of hemolysin production in mice infected with these strains alone, but one could argue that the presence of C. albicans could influence hemolysin levels. Studies are presently in progress to characterize the strains used in this study for hemolysin production and to test for synergistic effects between C. albicans and purified TS toxin as well as other enterotoxins and hemolysins.
The finding that all S. aureus strains acted synergistically with C. albicans to cause animal mortality was not unexpected in that we have found previously that candidal stimulation of bacterial infection is a general effect (5) . What is new and of interest in this study is that TS toxinproducing strains interacted with C. albicans to a far greater extent in this respect, with LD50s dropping in the presence of nonlethal doses of this fungus by three to four orders of magnitude, w.hereas LD50s of all other strains fell by only two orders of magnitude or less. It is interesting to note that previous reports have described a synergistic effect between C. albicans and gramnegative organisms on mouse mortality, but this effect could not be reproduced with the grampositive bacteria S. aureus, Streptococcus spp., and Bacillus subtilis (28) . It was therefore proposed that this bacterial-fungal synergism required gram-negative organisms (for a review, see reference 9). This apparent contradiction between our work and past findings could be explained by the difference in amount of synergism with C. albicans exhibited by various strains and species of Staphylococcus. Our findings further suggest that candidal stimulation of infecting bacterial is a general effect, but the degree of resulting mortality will depend on the array of toxins produced by the multiplying bacteria.
The disproportionally large stimulation of virulence by C. albicans of TS toxin-producing S. aureus strains and the unique dose-independent temporal death pattern in these dual infections suggest that C. albicans interacts with these strains in some way in addition to simple amplification of infecting numbers. Indeed, dual infections involving non-TSS-producing S. aureus of a low virulence equivalent to that of the TS toxin-producing strains resulted in no mortality increase when the bacterial dose was decreased to less than 1/10 its LD50 when inoculated alone.
A quantitative analysis of TS toxin production has not been done for the strains used in this study. It is noteworthy, however, that S. aureus FRI-1169, whose virulence was most stimulated by C. albicans, has been found to produce 5 to 10 times more TS toxin than the other TS toxinproducing strains tested (M. S. Bergdoll, personal communication).
Endotoxins have been proposed to play a role in TSS (21) . Pyrogenic exotoxin C (believed to be the same toxin as staphylococcal enterotoxin F or TS toxin [22] ) produced by TSS-associated S. aureus has been reported to amplify endotoxicity (17) . However, a source of the endotoxins in TSS in unknown. In this experimental system, one may speculate that C. albicans could possibly induce an inhibition of phagocytosis which would reduce the effectiveness of the elimination of the normal levels of endotoxins which is then amplified by the S. aureus-associated TS toxin. In addition, the ability of C. albicans to increase the host animals' production of histamine (19) and the ability of this substance to facilitate the passing of endotoxins from the gut into the bloodstream (11) may exacerbate the situation. Alternatively, C. albicans itself has been reported to produce substances with endotoxin-like properties (9, 13) .
It must be emphasized that the study reported here was not designed as a model for human disease, but rather to study further the fungalbacterial synergistic effect previously reported, and the system employed here is believed to optimize this effect. However, a number of similarities between the types of symptoms observed (conjunctivitis; gastrointestinal, neurological, and circulation abnormalities; rash followed by desquamation; and patchy baldness) in these dually infected animals and in human TSS patients (25) are noted. In addition, the impressive stimulation by C. albicans of virulence in the otherwise nonvirulent TS toxin-producing strains of S. aureus strengthens the possibility of a relationship between these organisms in disease. Thus, the combination of S. aureus and C. albicans may provide a model pathogen combination which could represent one condition leading to a unique TSS-like disease.
